Takeda Pharmaceutical Co Ltd Management Call Transcript
Before starting, I'd like to remind everyone that we'll be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause our actual results to differ materially are discussed in the most recent Form 20-F and in our other SEC filings. Please also refer to the important notice on Page 2 of the presentation.
Now please let me introduce today's presenters and panel: Christophe Weber, President and CEO; Andrew Plump, President of R&D; Costa Saroukos, Chief Financial Officer; and Ramona Sequeira, President, U.S. Business Unit and Global Portfolio Commercialization.
First, Christophe will give you a presentation. And after that, we will have a question-and-answer session. Now we would like to begin.
Thank you very much. It's a great pleasure to be with you. I wish we could be setting the meeting rooms
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |